Elizabeth Yeu Lin - 15 Mar 2026 Form 4 Insider Report for Tarsus Pharmaceuticals, Inc. (TARS)

Role
Chief Medical Officer
Signature
/s/ Jeffrey Farrow, Attorney-in-Fact
Issuer symbol
TARS
Transactions as of
15 Mar 2026
Net transactions value
$0
Form type
4
Filing time
17 Mar 2026, 16:20:11 UTC
Previous filing
09 Mar 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Lin Elizabeth Yeu Chief Medical Officer C/O TARSUS PHARMACEUTICALS, INC., 15440 LAGUNA CANYON ROAD, SUITE 160, IRVINE /s/ Jeffrey Farrow, Attorney-in-Fact 17 Mar 2026 0001842190

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TARS Common Stock Options Exercise +2,511 +11% 24,452 15 Mar 2026 Direct F1
holding TARS Common Stock 6,360 15 Mar 2026 By Spouse's Roth IRA
holding TARS Common Stock 12,040 15 Mar 2026 By 401(k) Plan

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TARS Restricted Stock Units Options Exercise -2,511 -25% $0.000000* 7,534 15 Mar 2026 Common Stock 2,511 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs").
F2 Each Restricted Stock Unit represents a contingent right to receive one share of the Company's common stock.
F3 RSUs granted on March 5, 2025, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2026, 2027, 2028 and 2029, subject to the Reporting Person's continuous service.